Roche's 2014 acquisition principle: small-scale acquisition of multi-domain layout
Looking back at the M&A events in the biomedical field in 2014, it’s hard not to be shocked by the “financial wealth†of these giants! The top M&A case comes from Actavis and Allergan’s $66 billion. Marriage, the deal also makes the combined company among the top ten pharmaceutical companies in the world. In addition, Actavis also acquired the branded drug manufacturer Forest Laboratories for $25 billion, which is also ranked third in the list. Ranked second in the list is US medical giant Medtronic's acquisition of Irish counterpart Covidien for $43 billion. Since 2014, there have been 9 mergers and acquisitions of more than $10 billion. It’s like, if you don’t play a multi-billion-dollar merger, you can’t call it a giant. However, there are exceptions to everything. The Swiss pharmaceutical company Roche has stepped out of its own path in this year's massive wave of acquisitions in the biomedical industry. In July, Roche CEO Severin Schwan said in an interview with a reporter from the Swiss Financial and Economic News that Roche plans to avoid a wave of large-scale acquisitions, focusing on small-scale acquisitions and cooperation. At the end of 2014, we also saw Roche's movements throughout the year confirming what Severin Schwan said. Roche’s biggest buy-and-sell deal this year was $8.3 billion In August of this year, Roche said that the company has agreed to acquire Intermune Biopharmaceutical Company in San Francisco for US$8.3 billion, and the transaction will be conducted in cash. This is Roche's biggest acquisition this year, and the acquisition will expand Roche's market share in the respiratory sector. Intermune has a new drug, pirfenidone, for the treatment of idiopathic fibrotic lung disease. The drug has been approved for marketing in several major countries in the world such as Europe, Canada, Japan and China, but the listing permit in the US is still under review. Also in August, it was reported that Roche was negotiating with its partner, Chugai, to acquire about 40% of the remaining shares of the latter for $10 billion, but in the end, Sino-foreign Pharmaceuticals denied the rumor. However, the big acquisitions are not, and the small acquisitions are really quite a lot. So, which companies will Roche receive in this year? First, in December, like the Chinese New Year in the New Year, Roche entered the crazy purchasing period in December, and has already acquired four companies. Crazy purchase December On December 2, Roche announced the acquisition of Ariosa Diagnostics, a company that specializes in digital targeted region selection and targeted region sequencing, and is accredited by CLIA (Clinical Laboratory Standards) for NIPT (Non-Invasive Prenatal Testing). Roche Diagnostics said the acquisition of Ariosa aims to expand the company's in vitro diagnostics business and enter the non-invasive prenatal testing industry. In mid-December, Roche Diagnostics signed an agreement with AvanSci Bio to purchase all products associated with high-performance microdissection of tissue sections on slides. The system uses instruments, software, and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis, including real-time PCR, microarrays, and sequencing. On December 20, Roche announced the acquisition of Bina Technologies, a bio-software technology company based in California. Bina has developed an integrated system for genomics data analysis, Bina-GMS (Genomic Management System), which enables genome-wide sequencing, whole exome sequencing, transcriptome sequencing, target region targeted sequencing, and more. data analysis. Bina will integrate with Roche's sequencing business unit in Q1 2015 and will develop a Bina-GMS system for Roche sequencing products to support data analysis from second to fourth generation sequencing products. In addition, Roche recently announced the acquisition of Austrian biotechnology company Dutalys for $489 million, an expert in the discovery and development of bispecific antibodies. Through the acquisition of Dutalys, Roche acquired the bispecific antibody platform DutaMab, which will provide novel bispecific antibody drugs for multiple therapeutic areas. Roche said the DutaMab platform will be complemented by its own bispecific antibody development system, CrossMab. The deal will strengthen Roche's leading position in therapeutic antibodies. Other acquisitions this year In October, in order to diversify Roche's diagnostic sequencing portfolio and acquire technology for related platforms, Roche announced the acquisition of primer-based targeted enrichment technology (PETE) from Abvitro. Abvitro is a company that detects therapeutic targets. The company's research shows that PETE is a very advanced technology, but not the part that they are most concerned about, so the company made the decision to sell the technology. In August, Roche announced a total of no more than $450 million to acquire Danish biopharmaceutical company Santaris Pharma. Under the agreement signed by the two parties, Roche will pay $250 million in advance and pay a balance of $200 million after the product reaches its target. Santaris Pharma is a Danish biopharmaceutical company founded in 2003 to develop antisense gene products using a unique locked-nucleic acid (LND) platform and tissue targeting technology. In July, Roche announced that it would pay $1.725 billion for the acquisition of Seragon Pharmaceuticals, a US biotechnology company. Seragon Pharmaceuticals is mainly researching breast cancer treatments, and Roche intends to increase its strength in breast cancer drugs through this acquisition. In June, Roche announced a bid of up to $350 million to acquire a privately owned company, Genia Technologies, which included milestone payments. Genia is developing a DNA sequencing platform. "With Genia's single-molecule semiconductor DNA sequencing platform using nanopore technology, our next-generation sequencing products will be enhanced," Roland Diggelmann, chief operating officer of Roche Diagnostics, said in a statement. In April, Roche announced that it had acquired IQuum for $450 million. The acquisition will allow Roche to quickly enter the Nursing Site (POC) segment of molecular diagnostics. IQuum's Liat system (Laboratory-in-a-tube) will be available to enable caregivers to conduct rapid molecular diagnostic tests closer to the patient's site. Roche's principle Schwan told reporters in an interview: "The first criterion for Roche's acquisition is to examine whether a product or technology has the potential to improve health standards, and the second is to examine whether the product or technology meets the company's two lines of business, namely, drugs and diagnostics." Schwan added: "The high valuation of pharmaceutical companies has curbed Roche's appetite for big deals. We have to weigh internal and external opportunities and not allow critical internal opportunities to be in crisis because of too expensive acquisitions." Bed Cover,Sms Bed Cover,Surgical Bed Cover,Disposable Bed Cover Xinxiang Huaxi Sanitary Materials Co., Ltd. , https://www.huaximedical.com